PITTSBURGH, Dec. 1, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today joins communities around the world to commemorate the 24th World AIDS Day by honoring those who have battled HIV/AIDS, celebrating the progress achieved to date in the global response to the disease, and reaffirming Mylan's passionate commitment to the ongoing fight against HIV/AIDS.
Mylan CEO Heather Bresch said, "Mylan is dedicated to expanding access to high quality antiretroviral medications (ARVs) for those in need. On this 24th World AIDS Day, we stand ready to continue contributing to the fight against HIV/AIDS in 2013 and beyond, and believe that an AIDS-free generation is within our grasp."
Mylan continues to support the pledge the U.S. government made on World AIDS Day 2011 to provide treatment to 6 million people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) by the end of 2013. PEPFAR was established in 2003 to help save those suffering from HIV/AIDS around the world. To date, the program has helped 4.5 million people in resource-limited areas receive treatment.
Mylan also continues to support the United Nations' "15 by 15" goal. If met, by 2015 the 15 million people who, according to the World Health Organization's (WHO) 2010 ARV Treatment Guidelines, need antiretroviral therapy would be receiving it.In order to increase and expand access to ARV medications used to treat HIV/AIDS, Mylan believes it is imperative to focus on enhancing mobility and supply-chain management. As a company with a proven track record for exemplary supply-chain management, Mylan is confident its insights can help shape the global community's efforts to improve access to this vital medicine. Bresch continued, "We are doing all we can to expand access to life-saving ARVs by scaling up to meet unmet needs and breaking down barriers that stand in the way of getting medicine to people who need it. For the last decade, Mylan has focused on driving down the costs of ARV medicines. Today, the primary barrier standing between patients and treatment is not the cost of drugs, but inadequate access to them. Our aim is to do for access what we already have done for affordability."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts